-+ 0.00%
-+ 0.00%
-+ 0.00%

Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

Barchart·09/21/2026 06:30:00
Listen to the news

Poster presentations further characterize clinical profile of HLP003 and 
Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment
for major depressive disorder (“MDD”)

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.